Zealand Pharma A/S (ZLDPF)

OTCMKTS · Delayed Price · Currency is USD
67.62
-1.70 (-2.45%)
May 28, 2025, 1:34 PM EDT
-19.73%
Market Cap 4.86B
Revenue (ttm) 8.07M
Net Income (ttm) -171.77M
Shares Out n/a
EPS (ttm) -2.50
PE Ratio n/a
Forward PE 5.03
Dividend n/a
Ex-Dividend Date n/a
Volume 252
Average Volume 767
Open 69.00
Previous Close 69.32
Day's Range 67.62 - 69.00
52-Week Range 57.97 - 141.74
Beta 0.56
RSI 56.44
Earnings Date May 8, 2025

About Zealand Pharma

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 335
Stock Exchange OTCMKTS
Ticker Symbol ZLDPF
Full Company Profile

Financial Performance

In 2024, Zealand Pharma's revenue was 62.69 million, a decrease of -81.71% compared to the previous year's 342.79 million. Losses were -1.08 billion, 53.3% more than in 2023.

Financial numbers in DKK Financial Statements

News

European stocks edge higher after Trump delays 50% tariffs on EU

European shares traded in positive territory on Monday.

2 days ago - CNBC

European stocks recover after Trump delays EU tariffs in hopes of deal

European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat to im...

2 days ago - Reuters

Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer...

9 days ago - GlobeNewsWire

Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.

12 days ago - Seeking Alpha

Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025

Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-n...

16 days ago - GlobeNewsWire

Zealand Pharma A/S (ZLDPF) Q1 2025 Earnings Call Transcript

Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsAdam Lange - Vice President, Investor...

19 days ago - Seeking Alpha

Zealand Pharma announces closing of collaboration and license agreement with Roche

Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand...

19 days ago - GlobeNewsWire

Zealand Pharma Announces Financial Results for the First Three Months of 2025

Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabi...

20 days ago - GlobeNewsWire

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion dealto develop Danish biotechZealand Pharma's "next generation" weight loss drug.

26 days ago - CNBC

Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq C...

27 days ago - GlobeNewsWire

Zealand Pharma says obesity drug deal with Roche will help it stay independent

Danish biotech is developing petrelintide in partnership with the Swiss pharma group

4 weeks ago - Financial Times

Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes

Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit...

4 weeks ago - Reuters

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Press release – No. 6 / 2025 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes The Phase 2b ZUPRE...

4 weeks ago - GlobeNewsWire

Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as i...

5 weeks ago - GlobeNewsWire

Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News

Zealand Pharma (ZLDPF) Launches 2025 Incentive Program | ZLDPF Stock News

5 weeks ago - GuruFocus

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Company announcement – No. 10 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhag...

5 weeks ago - GlobeNewsWire

Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025

Company announcement – No. 9 / 2025 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2025 Copenhagen, Denmark, April...

5 weeks ago - GlobeNewsWire

Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche

The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.

6 weeks ago - WSJ

Resolutions from Zealand Pharma's Annual General Meeting 2025

Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025 Copenhagen, Denmark, March 27, 2025 - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no.

2 months ago - GlobeNewsWire

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 6 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

2 months ago - GlobeNewsWire

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S (“Zealand”) (NA...

2 months ago - GlobeNewsWire

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phas...

2 months ago - GlobeNewsWire